Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Blood Cancer, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 15 - 59 |
| Updated: | 1/26/2019 |
| Start Date: | May 2006 |
Molecular Genetic Studies of Acute Myeloid Leukemia (AML) With Normal Cytogenetics. A CALGB Leukemia Tissue Bank Project
RATIONALE: Collecting and storing samples of tissue and blood from patients with cancer to
study in the laboratory may help doctors learn more about changes that may occur in DNA and
identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at changes in the DNA of tissue samples that were
collected from patients with acute myeloid leukemia.
study in the laboratory may help doctors learn more about changes that may occur in DNA and
identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at changes in the DNA of tissue samples that were
collected from patients with acute myeloid leukemia.
OBJECTIVES:
- Validate, on the larger number of patients with karyotypically normal acute myeloid
leukemia (AML) treated uniformly on CALGB-19808, preliminary results from CALGB-9621
showing that BAALC and ERG overexpression and microarray gene-expression signatures can
stratify the patients prognostically.
- Establish whether microRNAs are differentially expressed in subsets of patients with AML
and normal cytogenetics, and, if so, attempt to identify a signature that stratifies
patients prognostically.
- Explore the relative contribution in predicting clinical outcome of patients with
cytogenetically normal AML using genetic markers such as BAALC, ERG, and EVI1
overexpression, MLL partial tandem duplication, FLT3 internal tandem duplication, NPM1
and CEBPA mutations, and microarray gene expression microRNA signatures.
OUTLINE: This is a multicenter, pilot study.
Peripheral blood and bone marrow samples are analyzed to assess gene expression using
polymerase chain reaction (PCR) or reverse transcriptase-PCR assays and microarray assays.
Genes to be studied include BAALC, ERB, EVI1, MLL, FLT3, NPM1, and CEBPA.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
- Validate, on the larger number of patients with karyotypically normal acute myeloid
leukemia (AML) treated uniformly on CALGB-19808, preliminary results from CALGB-9621
showing that BAALC and ERG overexpression and microarray gene-expression signatures can
stratify the patients prognostically.
- Establish whether microRNAs are differentially expressed in subsets of patients with AML
and normal cytogenetics, and, if so, attempt to identify a signature that stratifies
patients prognostically.
- Explore the relative contribution in predicting clinical outcome of patients with
cytogenetically normal AML using genetic markers such as BAALC, ERG, and EVI1
overexpression, MLL partial tandem duplication, FLT3 internal tandem duplication, NPM1
and CEBPA mutations, and microarray gene expression microRNA signatures.
OUTLINE: This is a multicenter, pilot study.
Peripheral blood and bone marrow samples are analyzed to assess gene expression using
polymerase chain reaction (PCR) or reverse transcriptase-PCR assays and microarray assays.
Genes to be studied include BAALC, ERB, EVI1, MLL, FLT3, NPM1, and CEBPA.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
DISEASE CHARACTERISTICS:
- Diagnosis of acute myeloid leukemia
- Normal karyotype
- Bone marrow and/or peripheral blood samples from patients treated on CALGB-19808 and
registered on CALGB-9665 required
- No additional samples required
We found this trial at
1
site
Columbus, Ohio 43210
Click here to add this to my saved trials
